Digest Network Come funziona
Network
/
Società
Ve
Non verificato

VectorY Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
18/09/2025
Salute
Biotecnologia
Scienza
Farmaceutica
Mercato del lavoro
Industria
VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
27/05/2025
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
07/05/2025
Eventi
Biotecnologia
Salute
Medicina - Varie
VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
29/04/2025
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
VectorY Therapeutics Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy Annual Meeting 2025
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
01/04/2025
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
16/12/2024
Multimedialità
Biotecnologia
Farmaceutica
Scienza
Mercato del lavoro
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0
09/07/2024
Mercato del lavoro
Biotecnologia
Salute
Scienza
VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board
Fonte
VectorY Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0